Sustained beneficial effects of intraprostatic botulinum toxin type A on lower urinary tract symptoms and quality of life in men with benign prostatic hyperplasia

BJU International

Volumn 98, Issue 5, 2006, Pages 1033-1037

  Chuang, Yao Chi ^a   Chiang, Po Hui ^a   Yoshimura, Naoki ^b   De Miguel, Fernando ^b   Chancellor, Michael B ^b,c  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c Kaufmann Building ^*  (United States)

Author keywords

Botulinum toxin; BPH; LUTS; Prostate

Indexed keywords

BOTULINUM TOXIN A; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; FOLLOW UP; HUMAN; INTERNATIONAL PROSTATE SYMPTOM SCORE; LOWER URINARY TRACT SYMPTOM; MALE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; QUALITY OF LIFE; RESIDUAL URINE; SCORING SYSTEM; SINGLE DRUG DOSE; SMOOTH MUSCLE TONE; SYMPTOM; TRANSRECTAL ULTRASONOGRAPHY; URINARY TRACT DISEASE; URINE FLOW RATE; URINE RETENTION;

AGED; BOTULINUM TOXIN TYPE A; BOTULINUM TOXINS, TYPE A; HUMANS; INJECTIONS, INTRALESIONAL; MALE; NEUROMUSCULAR AGENTS; PROSTATIC HYPERPLASIA; PROSTATISM; QUALITY OF LIFE; TAIWAN; TREATMENT OUTCOME;

EID: 33749564739     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2006.06479.x     Document Type: Article

References (23)

1. Lepor H. The pathophysiology of lower urinary tract symptoms in the ageing male population. Br J Urol 1998; 81 (Suppl. 1): 29-33
2. Walsh PC. Treatment of benign prostatic hyperplasia. N Engl J Med 1996; 335: 586-7
3. AUA Practice Guidelines Committee. AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: diagnosis and treatment recommendations. J Urol 2003; 170: 530-47
4. Pennefather JN, Lau WA, Mitchelson F, Ventura S. The autonomic and sensory innervation of the smooth muscle of the prostate gland: a review of pharmacological and histological studies. J Auton Pharmacol 2000; 20: 193-206
5. Ventura S, Pennefather JN, Mitchelson F. Cholinergic innervation and function in the prostate gland. Pharmacol Ther 2002; 94: 93-112
6. Smith CP, Chancellor MB. Emerging role of botulinum toxin in the treatment of voiding dysfunction. J Urol 2004; 171: 2128-37
7. Smith CP, Franks ME, McNeil BK et al. Effect of botulinum toxin A on the autonomic nervous system of the rat lower urinary tract. J Urol 2003; 169: 1896-900
8. Chuang YC, Yoshimura N, Huang CC, Chiang PH, Chancellor MB. Intravesical botulinum toxin A administration produces analgesia against acetic acid induced bladder pain responses in rats. J Urol 2004; 172: 1529-32
9. Welch MJ, Purkiss JR, Foster KA. Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins. Toxicon 2000; 38: 245-58
10. Chuang YC, Chiang PH, Huang CC, Yoshimura N, Chancellor MB. Botulinum toxin type A improves benign prostatic hyperplasia symptoms in patients with small prostates. Urology 2005; 66: 775-9
11. Ravindranath N, Wion D, Brachet P, Djakiew D. Epidermal growth factor modulates the expression of vascular endothelial growth factor in the human prostate. J Androl 2001; 22: 432-43
12. McVary KT, McKenna KE, Lee C. Prostate innervation. Prostate Suppl 1998; 8: 2-13
13. Chuang YC, Huang CC, Kang HY et al. Novel action of botulinum toxin on the stromal and epithelial components of the prostate gland. J Urol 2006; 173: 1158-63
14. Maria G, Brisinda G, Civello IM, Bentivoglio AR, Sganga G, Albanese A. Relief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: results of a randomized, placebo-controlled study. Urology 2003; 62: 259-65
15. Kuo HC. Prostate botulinum toxin A injection - an alternative treatment for benign prostatic obstruction in poor surgical candidates. Urology 2005; 65: 670-4
16. Doggweiler R, Zermann DH, Ishigooka M, Schmidt RA. Botox-induced prostatic involution. Prostate 1998; 37: 44-50
17. Price H, McNeal JE, Stamey TA. Evolving patterns of tissue composition in benign prostatic hyperplasia as a function of specimen size. Hum Pathol 1990; 21: 578-85
18. Chuang YC, Yoshimura N, Huang CC et al. Intraprostatic capsaicin injection as a novel model for non-bacteria prostatitis. AUA Proceedings 2006: Abstract
19. Plante MK, Folsom JB, Zvara P. Prostatic tissue ablation by injection: a literature review. J Urol 2004; 172: 20-6
20. Chiang PH, Chuang YC, Huang CC, Chiang CP. Pilot study of transperineal injection of dehydrated ethanol in the treatment of prostatic obstruction. Urology 2003; 61: 797-801
21. Larson TR, Scottsdale AZ, Huidobro C, Acevedo C. Intraprostatic injection of botulinum toxin in the treatment of symptomatic LUTS, including sequential MRIS for accurate changes in size of the prostate. J Urol 2005; 173 (Suppl.): 376 (Abstract)
22. Guercini F, Giannantoni A, Bard RL et al. Intraprostatic botulin toxin injection in patients with severe benign prostatic hyperplasia a multicenter feasibility study. J Urol 2005; 173 (Suppl.): 376-7 (Abstract)
23. Chuang YC, Giannantoni A, Chancellor MB. The potential and promise of using botulinum toxin in the prostate gland. BJU Int 2006; 98: 28-32